79. Implications of fortuitous detection of JAK2 V617F mutations with solid tumor clinical sequencing

Genomic profiling of tumor provides valuable diagnostic, prognostic and therapeutic information. However, as clinical sequencing often relies on tumor-only approaches, factors such as infiltration from cells of hematopoietic lineage may confound accurate inference of variants present in tumor. We sought to investigate the frequency of a hallmark mutation in myeloid malignancies, JAK2 V617F, in solid tumor samples subjected to genetic testing at our institution and whether these underlie coexistence of a hematologic malignancy.

Source: Cancer Genetics and Cytogenetics - November 1, 2022 Category: Genetics & Stem Cells Authors: Marie-France Gagnon, Teja Koganti, Beth Pitel, Katherine Geiersbach Source Type: research